在非小细胞肺癌中对KRAS G12C抑制的抵抗性
Alessandro Di Federico1,2, Ilaria Ricciotti3, Valentina Favorito3
1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. alessandro_difederico@dfci.harvard.edu.
Current oncology reports
|June 28, 2023
概括
直接的KRASG12C抑制剂 (G12Ci) 对KRAS突变癌症有希望,但获得的耐药性限制了它们的有效性. 了解耐药机制是开发新疗法和改善患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 克拉斯突变驱动各种癌症,而克拉斯G12C是常见的致癌驱动因素.
- 直接的KRAS G12C抑制剂 (G12Ci) 在向癌症治疗方面取得了重大进展.
研究的目的:
- 描述获得对KRAS G12C抑制剂耐药性的多种机制.
- 识别治疗漏洞,并为未来的药物开发策略提供信息.
主要方法:
- 关于KRAS G12C抑制剂耐药性的最新科学文献的综述.
- 对目标和目标之外的阻力机制的分析.
- 探索组织学转变作为一种抵抗机制.
主要成果:
- 获得对G12Ci的耐药性是异质的,涉及到目标上 (例如,二级KRAS突变) 和目标之外的机制 (例如,途径改变,基因放大).
- 非目标耐药性包括下游路径的突变,瘤融合,基因复制增长以及其他信号路径的改变.
- 组织学转变也可能导致患者的一个子集的获得性耐药性.
结论:
- 了解获得性耐药性的多方面的机制对于克服治疗局限性至关重要.
- 需要克服或延迟耐药性的策略,以改善KRAS突变癌症患者的长期结果.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.0K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
相关概念视频
02:38The Ras Gene
6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.3K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K